Cerity Partners
MDGL icon

Cerity Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cerity Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$632K Buy
1,177
+7
+0.6% +$3.59K ﹤0.01% 2293
2026
Q1 		$612K Sell
1,170
-274
-19% -$131K ﹤0.01% 2159
2025
Q4 		$841K Buy
1,444
+481
+50% +$246K ﹤0.01% 1805
2025
Q3 		$442K Sell
963
-170
-15% -$63.4K ﹤0.01% 2056
2025
Q2 		$343K Sell
1,133
-278
-20% -$82.8K ﹤0.01% 2075
2025
Q1 		$467K Sell
1,411
-56
-4% -$18.4K ﹤0.01% 1794
2024
Q4 		$408K Buy
+1,467
New +$413K ﹤0.01% 1885
2024
Q3 		– Sell
-1,135
Closed -$318K – 2579
2024
Q2 		$318K Sell
1,135
-7
-0.6% -$1.67K ﹤0.01% 1787
2024
Q1 		$305K Buy
+1,142
New +$269K ﹤0.01% 1858
2023
Q2 		– Sell
-914
Closed -$221K – 1835
2023
Q1 		$221K Buy
914
+89
+11% +$24.3K ﹤0.01% 1665
2022
Q4 		$239K Buy
+825
New +$80.7K ﹤0.01% 1242

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cerity Partners's MDGL Position: Q2 2026 in Review

Cerity Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 0.6% in Q2 2026, buying an estimated $3.59K and bringing the position to 1,177 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Cerity Partners first reported a position in MDGL in Q4 2022 and has held it in 11 quarters since. The position peaked at $841K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Cerity Partners held 1,177 shares of Madrigal Pharmaceuticals worth $632K as of Q2 2026.
  • Cerity Partners bought 7 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $3.59K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2293 holding.
  • Cerity Partners first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
  • Cerity Partners's Madrigal Pharmaceuticals position peaked at $841K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.